Innovent Biologics Inc/ADR

Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection). In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.

Innovent Biologics, Inc.는 바이오 제약 회사로서 중화인민공화국, 미국, 유럽 및 전 세계적으로 항체 및 단백질 의약품 연구 개발에 주력하고 있습니다. 이 회사는 종양학, 안과, 자가면역, 심혈관 및 대사 질환 치료를 위한 단일클론 항체 및 기타 의약품을 발굴, 개발, 제조 및 상용화하고 있습니다. 상업화 단계의 제품 포트폴리오에는 TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), TABOSUN(Ipilimumab N01 injection) 등이 있습니다. 또한, 의약품 판매 및 유통뿐만 아니라 컨설팅 및 연구 개발 서비스도 제공하고 있습니다. 이 회사는 2011년에 설립되었으며, 중화인민공화국 쑤저우에 본사를 두고 있습니다.